Skip to main content
SpringerLink
Log in

ASH 2015 – stem cell transplantation

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Hematopoietic stem cell transplantation (HSCT) remains one of the most dynamic fields in hematology, as reflected by the large number of abstracts on new developments and establishing concepts in this scientific and clinical area, presented at the ASH meeting in December 2015. The role of haploidentical transplantation for recipients lacking an HLA-matched donor was further strengthened, and the use of an intelligently designed and carefully developed concept of immunomodulation, namely posttransplant cyclophosphamide, enabling successful transplantation across the multi-antigeneic HLA-barrier. Furthermore, with the development of novel antineoplastic therapies, both effective bridging to transplant, as well as prophylactic and preemptive interventions post HSCT will help increase the overall success of increasingly complex and individualized treatment concepts. Finally, novel cellular immunotherapies, most notably the genetically engineered chimeric antigen receptor (CAR) T cell concepts, will extend the therapeutic options for patients with hematological malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clausen J. ASH 2012: Allogeneic stem cell transplantation. Memo. 2013;6(3):174–6.

    Article  Google Scholar 

  2. Gaballa S, et al. Results of a two-arm phase II clinical trial using post-transplantation cyclophosphamide for prevention of graft-versus-host disease in haploidentical and mismatched unrelated donors hematopoietic stem-cell transplantation. Blood. 2015;126:152.

    Google Scholar 

  3. Lee K‑H, et al. Allogeneic hematopoietic cell transplantation for acute myelogenous leukemia in remission – a prospective comparison of three different donor groups; matched sibling, matched unrelated, and haploidentical family donors. Blood. 2015;126:4379.

    Article  Google Scholar 

  4. Wang Y, et al. Stem-cell transplantation in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia in first complete remission: a prospective multicenter trial comparing haploidentical donors with identical sibling donors. Blood. 2015;126:62.

    Google Scholar 

  5. Lorentino F, et al. HLA disparities impact on outcomes after unmanipulated haploidentical hematopoietic stem cells transplantation (HaploSCT) in acute leukemia: a study from the acute leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2015;126:399.

    Google Scholar 

  6. Mussetti A, et al. Survival after T-cell replete haploidentical related donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor (MUD) transplant for lymphoid malignancies. Blood. 2015;126:194.

    Google Scholar 

  7. Martinez C, et al. Alternative donors (umbilical cord blood and haploidentical donors) for allogeneic stem cell transplantation in relapsed/refractory hodgkin lymphoma: a retrospective analysis of the EBMT lymphoma working party and the spanish group of stem cell transplantation (GETH). Blood. 2015;126:4399.

    Google Scholar 

  8. Bertaina A, et al. Children with acute leukemia given hematopoietic stem cell transplantation (HSCT) from an HLA-compatible sibling, or an unrelated donor (UD) or an HLA-haploidentical relative after alpha/beta T-cell depletion have a comparable outcome. Blood. 2015;126:195.

    Article  Google Scholar 

  9. Zhao Y‑L, et al. Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases. Blood. 2015;126:3224.

    Google Scholar 

  10. Kasamon YL, et al. Nonmyeloablative (NMA), HLA-mismatched unrelated donor (mMUD) BMT with high-dose posttransplantation cyclophosphamide (PTCy) has outcomes similar to matched BMT. Blood. 2015;126:2002.

    Google Scholar 

  11. Schlenk R, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine (NCT01477606). Blood. 2015;126:322.

    Google Scholar 

  12. Brunner AM, et al. Hematopoietic cell transplantation with or without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukemia in CR1. Blood. 2015;126:864.

    Google Scholar 

  13. Pratz KW, et al. Prospective study of peri-transplant use of sorafenib as remission maintenance for FLT3-ITD patients undergoing allogeneic transplantation. Blood. 2015;126:3164.

    Google Scholar 

  14. Bug G, et al. Phase I/II study of the deacetylase inhibitor panobinostat as maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: the panobest-trial. Blood. 2015;126:4344.

    Google Scholar 

  15. Luger S, et al. Tipifarnib as maintenance therapy in acute myeloid leukemia (AML) improves survival in a subgroup of patients with high risk disease. Results of the phase III intergroup trial E2902. Blood. 2015;126:1308.

    Google Scholar 

  16. Shipton MJ, et al. Seattle regimen RIC-HSCT in early-phase multiple myeloma: a multi-centre experience demonstrating very low treatment-related mortality and rapid graft-versus-myeloma effect associated with graft-versus-host disease. Blood. 2015;126:4355.

    Google Scholar 

  17. Schmid C, et al. Efficacy, safety and long term results of prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia: a registry-based evaluation on 343 patients by the acute leukemia working party of EBMT. Blood. 2015;126:863.

    Article  Google Scholar 

  18. Mehta RS, et al. Post-transplantation high dose cyclophosphamide as gvhd prophylaxis in 9/10 HLA-matched unrelated donors hematopoietic stem cell transplantation. Blood. 2015;126:3135.

    Google Scholar 

  19. Khoury HJ, et al. Outcomes of grades II–IV acute graft-versus-host disease post-allogeneic hematopoietic stem cell transplantation: how much progress was achieved? Blood. 2015;126:3132.

    Google Scholar 

  20. Clausen J. New approaches in graft versus host disease (GvHD) management. Memo. 2016;9(1):45–7.

    Article  Google Scholar 

  21. Peled J, et al. The abundance of certain bacteria in the intestinal flora is associated with relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2015;126:744.

    Google Scholar 

  22. Routy B, et al. Influence of prophylactic antibiotics aiming at gut decontamination on gastrointestinal graft-versus-host disease and overall survival following allogeneic haematopoietic stem cell transplantation. Blood. 2015;126:4319.

    Google Scholar 

  23. Atallah E, et al. Outcome of patients 65 years and older with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation compared to patients 55–64 years of age. Blood. 2015;126:193.

    Google Scholar 

  24. Attal M, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial). Blood. 2015;126:391.

    Google Scholar 

  25. Cook G, et al. A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): results from the myeloma X (intensive) trial. Blood. 2015;126:394.

    Google Scholar 

  26. Maude SL, et al. Efficacy and safety of humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 in children with relapsed/ refractory ALL. Blood. 2015;126:683.

    Article  Google Scholar 

  27. Curran KJ, et al. Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL. Blood. 2015;126:2533.

    Article  Google Scholar 

  28. Enblad G, et al. Third generation CD19-CAR T cells for relapsed and refractory lymphoma and leukemia report from the swedish phase I/IIa trial. Blood. 2015;126:1534.

    Google Scholar 

  29. Danhof S, et al. CAR-engineered T cells specific for the elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets. Blood. 2015;126:115.

    Google Scholar 

  30. Arcangeli S, et al. CAR-engineered T cells specific for the elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets. Blood. 2015;126:1359.

    Google Scholar 

  31. Kebriaei P, et al. Pre-emptive donor lymphocyte infusion with CD19-directed, CAR-modified T cells infused after allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies. Blood. 2015;126:862.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Devision of Stem Cell Transplantation, 1, Elisabethinen Hospital Linz, Fadingerstr. 1, 4020, Linz, Austria

    Johannes Clausen MD

Authors
  1. Johannes Clausen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Clausen MD.

Ethics declarations

Conflict of interest

J. Clausen declares that he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clausen, J. ASH 2015 – stem cell transplantation. memo 9, 136–138 (2016). https://doi.org/10.1007/s12254-016-0276-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-016-0276-2

Keywords

Search

Navigation